PYC Therapeutics Advances PKD Drug with Phase 1b Trial

First Patient Dosed in Phase 1b Trial for PKD

PYC Therapeutics (ASX:PYC) has reached a key milestone by dosing the first patient in its Phase 1b Multiple Ascending Dose (MAD) clinical trial of PYC-003, a drug candidate designed to tackle the root cause of Polycystic Kidney Disease (PKD). This marks a significant step forward for the biotech firm’s precision medicine approach targeting genetic diseases with no current treatment options.

The MAD study aims to establish the safety and tolerability of repeated doses of PYC-003 in PKD patients, while also measuring multiple efficacy-related endpoints such as urinary polycystin-1 (PC1) protein levels, total kidney volume via MRI, and estimated glomerular filtration rate (eGFR). These biomarkers are critical in assessing whether PYC-003 can effectively increase PC1 protein expression in kidneys, a therapeutic goal that could alter disease progression.

Clinical Development Pathway and Regulatory Ambitions

The ongoing Phase 1b MAD study follows an earlier Phase 1a Single Ascending Dose (SAD) study, with data from the latter expected to be presented in the second half of 2026. Results from the MAD study are anticipated in 2027, contingent on trial progression and regulatory alignment. Successful outcomes could pave the way for a registrational combined Phase 2/3 trial, which would support a New Drug Application for PYC-003.

This clinical progression aligns with PYC’s broader strategy to advance RNA therapies for monogenic diseases, leveraging their proprietary delivery platform to enhance drug potency. The company’s recent highest dose cohort in PKD advancement underscores momentum in this program, supported by a robust capital position following a $600 million raise earlier in 2026.

Positioning Within PYC’s Expanding Pipeline

PYC-003’s development is part of a diversified pipeline that includes RNA therapies for genetic eye diseases such as Autosomal Dominant Optic Atrophy (ADOA) and Retinitis Pigmentosa type 11 (RP11). The company recently advanced its eye disease candidate PYC-001 to multiple dose studies, reflecting a concerted push to validate repeated dosing regimens across its portfolio. These parallel efforts highlight PYC’s commitment to clinical rigor and regulatory readiness across indications.

While the PKD program targets a disease with significant unmet need, the path to regulatory approval remains subject to the usual clinical and regulatory uncertainties. The company’s disclosures caution that timelines and outcomes depend on trial results and alignment with authorities, a reminder of the inherent risks in early-stage biotech development.